• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban.
This article will introduce and provide context for these RCTs in the contemporary management of arterial and venous thromboembolism in the following underserved areas: Patients with both NVAF and acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI); patients with embolic stroke of undetermined source (ESUS); patients who require transcatheter aortic valve replacement (TAVR); patients with acute or chronic coronary artery disease (CAD; including those with heart failure [HF]); those at risk of or suffering from cancer-associated thrombosis (CAT) and those requiring long-term anticoagulation. It ...
Source: Thrombosis and Haemostasis - September 13, 2016 Category: Hematology Authors: Cappato R, Welsh R Tags: Thromb Haemost Source Type: research

Intra-hospital correlations among 30-day mortality rates in 18 different clinical and surgical settings
Conclusions</div>The variability in 30-day mortality rates at hospital level and the correlation between risk mortality rates suggest that there may be common hospital-wide factors influencing short-term mortality.</span>
Source: International Journal for Quality in Health Care - January 31, 2017 Category: Global & Universal Source Type: research

Impact of active cancer disease on the outcome of patients undergoing transcatheter aortic valve replacement
ConclusionThe presence of ACD in patients undergoing TAVR is associated with significantly higher 1‐year mortality.
Source: Journal of Interventional Cardiology - November 22, 2017 Category: Cardiology Authors: Norman Mangner, Felix J. Woitek, Stephan Haussig, David Holzhey, Georg Stachel, Florian Schlotter, Robert H öllriegel, Friedrich W. Mohr, Gerhard Schuler, Axel Linke Tags: ORIGINAL INVESTIGATION Source Type: research

3 Reasons TAVR Will Continue to Prosper
The transcatheter aortic valve replacement (TAVR) market has already seen rapid growth, and today represents a $3 billion market globally. But the leading TAVR companies say the current technology and approved indications barely scratches the surface in terms of the true growth potential of the space. Michael Mussallem, CEO of Edwards Lifesciences, told J.P. Morgan Healthcare Conference attendees on Monday that the global TAVR market is expected to exceed $5 billion by 2021, and that number does not include certain indications that are currently being explored, like treatment for patients with asymptomatic aortic stenosi...
Source: MDDI - January 9, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Prognosis of Cancer Patients with Aortic Stenosis Under Optimal Cancer Therapies and Conservative Cardiac Treatments.
Authors: Okura Y, Ishigaki S, Sakakibara S, Yumoto C, Hashitate M, Sekine C, Fujita T, Takayama T, Ozaki K, Sato N, Minamino T Abstract Aortic stenosis (AS) is a life-threatening comorbidity of cancer patients. Aortic valve replacement (AVR) should be considered for some cancer patients, but neither the characteristics nor prognosis under conservative therapy is well known.We searched our echocardiography log (years 2005-2014) for cancer patients with AS, and 92 patients (54% female) were included in the study. To compare the survival curves, 470 control patients without AS were selected from our cancer registry.Me...
Source: International Heart Journal - June 9, 2018 Category: Cardiology Tags: Int Heart J Source Type: research

Mid-term valve stability after valve sparing aortic root replacement: Outcomes in bicuspid aortic valve compared with tricuspid aortic valve
ConclusionVSRR ensures excellent mid-term aortic valve function independently of its morphology. In B associated with aortic root aneurysm, leaflet repair does not increase the valve-related events.
Source: Archives of Cardiovascular Diseases Supplements - January 7, 2020 Category: Cardiology Source Type: research

Clonal Hematopoiesis and the Heart: a Toxic Relationship
AbstractPurpose of ReviewClonal hematopoiesis (CH) refers to the expansion of hematopoietic stem cell clones and their cellular progeny due to somatic mutations, mosaic chromosomal alterations (mCAs), or copy number variants which naturally accumulate with age. CH has been linked to increased risk of blood cancers, but CH has also been linked to adverse cardiovascular outcomes.Recent FindingsA combination of clinical outcome studies and mouse models have offered strong evidence that CH mutations either correlate with or cause atherosclerosis, diabetes mellitus, chronic kidney disease, heart failure, pulmonary hypertensi...
Source: Current Oncology Reports - March 15, 2023 Category: Cancer & Oncology Source Type: research

Pages: 1  2